HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. About 55 participants will receive the combination, and researchers will measure how man…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill INX-315 takes on advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can two cancer pills keep breast cancer from returning?
Disease control Recruiting nowThis study is looking at whether taking a CDK4/6 inhibitor (either abemaciclib or ribociclib) after surgery can help prevent breast cancer from coming back in people with HR+/HER2- breast cancer. The researchers will follow 229 participants to see how long they stay cancer-free a…
Matched conditions: HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Sponsor: Wenjin Yin • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC